Abstract:
The article presents modern approaches to the early diagnosis of AD. Alzheimer's disease (AD) is a widespread disease worldwide. According to experts from the World Health Organization, asthma is the most common cause of dementia in the elderly and senile. None of the currently known biomarkers with independent use in the clinic can fulfill the role of a decisive factor in establishing the diagnosis of AD. This is primarily due to the cross-determination of known biomarkers correlated with the course of asthma in other pathologies of the nervous system. In this regard, we hypothesized the integrated use of
the most important biomarkers for early diagnosis, monitoring the effectiveness of therapy and identifying AD risk groups. The essence of the hypothesis is the simultaneous determination in patients of a number of biomarkers (dehydroepiandrosterone sulfate (DHEA-s), apolipoprotein E4 (Apo-E4) and beta-amyloid protein (Aß 1-42) and, when discriminating levels of these compounds are established, the development of the corresponding the diagnosis or classification of a patient at risk for developing AD.
The study aimed compare clinical and laboratory data in the early diagnosis of AD. Laboratory tests were carried out using the enzyme immunoassay determination of the level of DHEA (dehydroepiandrosterone) before and after the oxidation of the catalyst with Fe2+. When studying the DHEA level in blood serum before and after oxidation with a catalyst, the level of DHEA was insignificant or absent in patients with AD, while the level of DHEA in patients without AD increased sharply. The new diagnostic method proposed by us showed a differential diagnosis of AD.
